Prevalence of fluoroquinolone-resistant Salmonella serotypes in Iran: a meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 101583421 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-7732 (Electronic) Linking ISSN: 20477724 NLM ISO Abbreviation: Pathog Glob Health Subsets: MEDLINE
    • Publication Information:
      Publication: 2016- : Abingdon : Taylor & Francis
      Original Publication: London, UK : Maney Pub.
    • Subject Terms:
      Drug Resistance, Bacterial*; Anti-Bacterial Agents/*pharmacology ; Fluoroquinolones/*pharmacology ; Salmonella/*drug effects ; Salmonella Infections/*microbiology; Humans ; Iran/epidemiology ; Salmonella/classification ; Salmonella/genetics ; Salmonella/isolation & purification ; Salmonella Infections/drug therapy ; Salmonella Infections/epidemiology
    • Abstract:
      The present study was conducted to investigate the antimicrobial susceptibility profiles of Salmonella serotypes, especially fluoroquinolone-resistant strains, recovered from clinical samples in Iran. A full electronic search using related keywords was conducted in Persian and English languages in ISI Web of Knowledge, PubMed, Scopus, Google Scholar and the Scientific Information Database (SID) search engines to find papers published between 1983 and 1 July 2019. According to the inclusion and exclusion criteria, 46 eligible articles were selected for the final analysis out of the initial 13,186 studies retrieved. The pooled prevalence of quinolone-resistant Salmonella serotypes in clinical specimens in Iran was 2.9% to ciprofloxacin and 48.1% to nalidixic acid. Additional data on antibiotic resistance was as follows: 54.3% to tetracycline, 50.6% to ceftizoxime, 50.2% to streptomycin, 37.9% to ampicillin, 36.5% to kanamycin, 33.5% to trimethoprim-sulfamethoxazole, 27.2% to chloramphenicol, 19.1% to cephalothin, 8.8% to ceftriaxone, 7.6% to cefotaxime, 7.4% to aztreonam, 7.2% to gentamicin, 7% to cefepime, 6.8% to ceftazidime, 5.8% to cefixime, 2.7% to imipenem and 2.2% to meropenem. Findings of the present study showed a rising trend of resistance to the drugs of choice for the treatment of Salmonella infections, i.e. ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole in Iran. However, ciprofloxacin, third-generation cephalosporins and carbapenems are still effective antibiotics especially against multi-drug resistant strains in Iran.
    • References:
      Microb Drug Resist. 2018 May;24(4):479-488. (PMID: 29293397)
      PLoS Negl Trop Dis. 2018 Oct 11;12(10):e0006779. (PMID: 30307935)
      PLoS One. 2013;8(3):e57439. (PMID: 23526942)
      J Res Health Sci. 2007 Jul 28;7(1):49-56. (PMID: 23343871)
      Infect Disord Drug Targets. 2019 Jan 30;:. (PMID: 30706828)
      Int J Antimicrob Agents. 2011 Apr;37(4):360-4. (PMID: 21371866)
      Jpn J Infect Dis. 2009 Sep;62(5):368-71. (PMID: 19762986)
      Eur J Microbiol Immunol (Bp). 2017 Apr 26;7(2):133-137. (PMID: 28690880)
      Infect Dis (Lond). 2016 Jul;48(7):550-6. (PMID: 27117981)
      Scand J Infect Dis. 1997;29(3):265-9. (PMID: 9255887)
      PLoS Med. 2009 Jul 21;6(7):e1000100. (PMID: 19621070)
      Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S165-S170. (PMID: 30845331)
      Clin Infect Dis. 2004 Aug 15;39(4):546-51. (PMID: 15356819)
      J Clin Microbiol. 2006 Mar;44(3):700-8. (PMID: 16517842)
      Gut Pathog. 2016 Jun 13;8:31. (PMID: 27303446)
      J Infect Dev Ctries. 2012 Feb 13;6(2):120-5. (PMID: 22337839)
      Scand J Infect Dis. 1990;22(2):197-203. (PMID: 2356442)
      Iran J Microbiol. 2015 Aug;7(4):203-7. (PMID: 26697159)
      Iran J Microbiol. 2018 Oct;10(5):294-299. (PMID: 30675325)
      Iran J Med Sci. 2017 Sep;42(5):443-448. (PMID: 29234176)
      Open Microbiol J. 2017 Sep 21;11:189-194. (PMID: 29151995)
      Ital J Food Saf. 2019 Jun 25;8(2):8233. (PMID: 31355156)
      Iran J Microbiol. 2011 Sep;3(3):112-7. (PMID: 22347592)
      Gastroenterol Hepatol Bed Bench. 2018 Winter;11(1):54-59. (PMID: 29564066)
      Osong Public Health Res Perspect. 2017 Jun;8(3):211-219. (PMID: 28781944)
      Jundishapur J Microbiol. 2014 May;7(5):e9924. (PMID: 25147720)
      New Microbiol. 2010 Jan;33(1):47-56. (PMID: 20402413)
      Jpn J Infect Dis. 2010 Nov;63(6):417-21. (PMID: 21099092)
      Int J Evid Based Healthc. 2015 Sep;13(3):147-53. (PMID: 26317388)
      Foodborne Pathog Dis. 2011 Apr;8(4):547-53. (PMID: 21204690)
      Microb Drug Resist. 2017 Dec;23(8):1037-1044. (PMID: 29106325)
      Folia Microbiol (Praha). 2012 Mar;57(2):91-7. (PMID: 22307834)
      J Glob Antimicrob Resist. 2018 Mar;12:220-226. (PMID: 29045813)
      FEMS Microbiol Rev. 2012 May;36(3):600-15. (PMID: 22335190)
      Jundishapur J Microbiol. 2016 Apr 17;9(4):e26505. (PMID: 27284396)
    • Contributed Indexing:
      Keywords: Antibiotic resistance; Iran; Salmonella; fluoroquinolone
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Fluoroquinolones)
    • Publication Date:
      Date Created: 20200205 Date Completed: 20201209 Latest Revision: 20210206
    • Publication Date:
      20240829
    • Accession Number:
      PMC7144288
    • Accession Number:
      10.1080/20477724.2020.1719701
    • Accession Number:
      32013798